MX2022009874A - Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4). - Google Patents
Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4).Info
- Publication number
- MX2022009874A MX2022009874A MX2022009874A MX2022009874A MX2022009874A MX 2022009874 A MX2022009874 A MX 2022009874A MX 2022009874 A MX2022009874 A MX 2022009874A MX 2022009874 A MX2022009874 A MX 2022009874A MX 2022009874 A MX2022009874 A MX 2022009874A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- heterocyclic
- pad4
- pad4 inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Luminescent Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere a compuestos heterocíclicos sustituidos de la Fórmula (Ia), que son inhibidores de PAD4, método para preparar estos compuestos, composiciones farmacéuticas que comprenden estos compuestos y uso de estos compuestos en el tratamiento de una enfermedad o trastorno asociado con la actividad de la enzima PAD4. (ver Fórmula) (Ia) en donde (ver Fórmulas) es; (ver Fórmulas) es; y X1-X6 y R1-R8, junto con otras variables son como se definen en la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202041006146 | 2020-02-12 | ||
PCT/US2021/017554 WO2021163254A1 (en) | 2020-02-12 | 2021-02-11 | Heterocyclic pad4 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022009874A true MX2022009874A (es) | 2022-08-22 |
Family
ID=74856949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022009874A MX2022009874A (es) | 2020-02-12 | 2021-02-11 | Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4). |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230167131A1 (es) |
EP (1) | EP4103559A1 (es) |
JP (1) | JP2023515780A (es) |
KR (1) | KR20220140795A (es) |
CN (1) | CN115348961A (es) |
AR (1) | AR121299A1 (es) |
AU (1) | AU2021219710A1 (es) |
BR (1) | BR112022015792A2 (es) |
CA (1) | CA3167753A1 (es) |
CL (1) | CL2022002148A1 (es) |
CO (1) | CO2022011388A2 (es) |
IL (1) | IL295506A (es) |
MX (1) | MX2022009874A (es) |
PE (1) | PE20230679A1 (es) |
TW (1) | TW202140477A (es) |
WO (1) | WO2021163254A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112022021963A2 (pt) | 2020-04-30 | 2022-12-13 | Gilead Sciences Inc | Inibidores macrocíclicos de peptidilarginina desiminases |
EP4267562A1 (en) | 2020-12-22 | 2023-11-01 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7842713B2 (en) | 2006-04-20 | 2010-11-30 | Pfizer Inc | Fused phenyl amido heterocyclic compounds |
US9127003B2 (en) * | 2012-07-26 | 2015-09-08 | Glaxo Group Limited | 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors |
US10407407B2 (en) * | 2015-05-21 | 2019-09-10 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as PAD4 inhibitors |
AR107030A1 (es) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | Inhibidores aza-bencimidazol de pad4 |
CA3007025A1 (en) * | 2015-12-22 | 2017-06-29 | Kancera Ab | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity |
CN110582489B (zh) * | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
DK3697785T3 (da) * | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Imidazo-pyridine forbindelser som pad-inhibitorer |
-
2021
- 2021-02-09 TW TW110105125A patent/TW202140477A/zh unknown
- 2021-02-10 AR ARP210100336A patent/AR121299A1/es unknown
- 2021-02-11 PE PE2022001712A patent/PE20230679A1/es unknown
- 2021-02-11 WO PCT/US2021/017554 patent/WO2021163254A1/en active Application Filing
- 2021-02-11 EP EP21709851.6A patent/EP4103559A1/en active Pending
- 2021-02-11 CN CN202180025726.9A patent/CN115348961A/zh active Pending
- 2021-02-11 MX MX2022009874A patent/MX2022009874A/es unknown
- 2021-02-11 JP JP2022548707A patent/JP2023515780A/ja active Pending
- 2021-02-11 IL IL295506A patent/IL295506A/en unknown
- 2021-02-11 CA CA3167753A patent/CA3167753A1/en active Pending
- 2021-02-11 BR BR112022015792A patent/BR112022015792A2/pt not_active Application Discontinuation
- 2021-02-11 AU AU2021219710A patent/AU2021219710A1/en active Pending
- 2021-02-11 KR KR1020227031398A patent/KR20220140795A/ko unknown
- 2021-02-11 US US17/799,028 patent/US20230167131A1/en active Pending
-
2022
- 2022-08-10 CL CL2022002148A patent/CL2022002148A1/es unknown
- 2022-08-12 CO CONC2022/0011388A patent/CO2022011388A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR121299A1 (es) | 2022-05-04 |
KR20220140795A (ko) | 2022-10-18 |
JP2023515780A (ja) | 2023-04-14 |
IL295506A (en) | 2022-10-01 |
CO2022011388A2 (es) | 2022-08-30 |
AU2021219710A1 (en) | 2022-10-06 |
PE20230679A1 (es) | 2023-04-21 |
CL2022002148A1 (es) | 2023-02-24 |
EP4103559A1 (en) | 2022-12-21 |
BR112022015792A2 (pt) | 2022-10-11 |
US20230167131A1 (en) | 2023-06-01 |
TW202140477A (zh) | 2021-11-01 |
CA3167753A1 (en) | 2021-08-19 |
WO2021163254A1 (en) | 2021-08-19 |
CN115348961A (zh) | 2022-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500395A1 (en) | Amino-pyrrolopyrimidinone compounds and methods of use thereof | |
MX2021013110A (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
PH12020500203A1 (en) | Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors | |
WO2016118951A3 (en) | Heterocyclic itk inhibitors for treating inflammation and cancer | |
MX2007004248A (es) | Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa. | |
MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
EA201190158A1 (ru) | Производные бензофуранила для применения в качестве ингибиторов глюкокиназы | |
PL2324008T3 (pl) | 3,4-diarylopirazole jako inhibitory kinazy białkowej | |
EP2571876A4 (en) | SUBSTITUTED SEVEN-HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV INHIBITORS FOR THE TREATMENT OF DIABETES | |
MX2022016463A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
HK1136292A1 (en) | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
AU2009258496A8 (en) | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity | |
BRPI1015568B8 (pt) | derivados de imidazolidin-2-ona 1,3-dissubstituídos como inibidores de cyp 17, seus usos, e composição farmacêutica | |
UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
PH12020552135A1 (en) | Kdm1a inhibitors for the treatment of disease | |
NZ597075A (en) | 1, 2, 4-thiazolidin-3-one derivatives as AMP-activated protein kinase (AMPK) agonists for treating cancer | |
MX2009011276A (es) | Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad. | |
MY160004A (en) | Heterocyclically substituted aryl compounds as hif inhibitors | |
TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
MX2011011083A (es) | Compuestos heterociclicos como inhibidores de mek. | |
GEP20115342B (en) | New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them | |
MX2022009874A (es) | Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4). | |
MX2017011277A (es) | Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades. | |
NZ726695A (en) | Gls1 inhibitors for treating disease |